10:21 PM | January 27, 2012

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of
LUVOX CR®(fluvoxamine maleate) Extended-Release Capsules or any other antidepressant in a child, adolescent, or young adult must balance the risk with a clinical need. Short-term studies did not show an increase in this risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders and themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. (See WARNINGS AND PRECAUTIONS - Clinical Worsening and Suicide Risk and USE IN SPECIFIC POPULATIONS - Pediatric Use.)

Once-A-Day LUVOX CR® (fluvoxamine maleate)
 Extended-Release Capsules

Indicated for Obsessive Compulsive Disorder (OCD), as defined in the DSM-IV.

Information for Patients

LUVOX CR PatientLearn more about LUVOX CR >>

LUVOX CR is a Once-A-Day medication that is taken at bedtime for the treatment of OCD, as defined in the DSM-IV.

 

 

Information for Healthcare Professionals

LUVOX CR Healthcare ProfessionalLearn more about LUVOX CR >>

Once-A-Day LUVOX CR (fluvoxamine maleate) Extended-Release Capsules are indicated for the treatment of OCD, as defined
in the DSM-IV.


  • Proven efficacy in OCD[1][2]
  • Weight-neutral profile (no significant weight gain or loss) vs. placebo in 12 week clinical trials[1][2][3][4]
  • SODAS® (Spheroidal Oral Drug Absorption System) technology designed to minimize peak to trough plasma level fluctuations over a 24-hour period
  • Available in 100 mg and 150 mg dose strengths
  • Taken at bedtime with or without food

    Adverse Events

  • In clinical trials, the most commonly observed adverse reactions with an incidence of ≥5% and at least twice that of placebo were nausea, somnolence, asthenia, diarrhea, anorexia, abnormal ejaculation, tremor, sweating, and anorgasmia.
  • In one controlled trial in patients with OCD, the following additional reactions occurred at an incidence of 5% or greater and at least twice that for placebo: anxiety, decreased libido, vomiting, pharyngitis and myalgia.
  • In clinical trials, discontinuation rates due to an adverse reaction were 19% for the OCD population (N=124) and 26% in another studied population (N=279).
OCD Self-Assessment
What do your obsessions compel
you to do?
Begin

Healthcare Professionals
Get important facts and information about LUVOX CR.
PharmacistPhysician

Questions about LUVOX CR
We're here to help. We welcome your inquiries.
Ask Us

Adverse Event Reporting

To report an adverse event please call 1-800-520-5568

Once-A-Day LUVOX CR® (fluvoxamine maleate) Extended-Release Capsules are indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM-IV.

Important Safety Information

CONTRAINDICATIONS

  • The use of thioridazine, tizanidine, pimozide, alosetron or ramelteon with LUVOX CR Capsules is contraindicated.
  • The use of MAO inhibitors in combination with LUVOX CR Capsules, or within 2 weeks of discontinuing treatment with LUVOX CR Capsules is contraindicated. Also, LUVOX CR Capsules should not be administered within 14 days (2 weeks) after discontinuing treatment with an MAOI (See WARNINGS AND PRECAUTIONS).
  • Development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including LUVOX CR treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs that impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine agonists.
  • See WARNINGS AND PRECAUTIONS for other important safety information, including information about drug interactions.

ADVERSE EVENTS

  • In clinical trials, the most commonly observed adverse events with an incidence of ≥5% and at least twice that of placebo were nausea, somnolence, asthenia, diarrhea, anorexia, abnormal ejaculation, tremor, sweating, and anorgasmia.
  • In one controlled trial in patients with OCD, the following additional reactions occurred at an incidence of 5% or greater and at least twice that for placebo: anxiety, decreased libido, vomiting, pharyngitis and myalgia.
  • In clinical trials, discontinuation rates due to an adverse reaction were 19% for the OCD population (N=124) and 26% in another studied population (N=279). [2]

DOSING CONSIDERATIONS

  • A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. There have been spontaneous reports of adverse reactions occurring upon discontinuation of SSRIs and SNRIs, particularly when abrupt. Patients should be monitored for these symptoms when discontinuing treatment with LUVOX CR Capsules.
  • SSRIs and SNRIs, including LUVOX CR may increase the risk of bleeding events. Concomitant use of fluvoxamine, NSAIDs, aspirin, warfarin, or other drugs that affect coagulation, should be cautioned.
  • LUVOX CR may impair judgment, thinking, or motor skills; patients should be cautioned until they have adapted to therapy.
  • Screen and monitor for depression, suicidality, and bi-polar disorder.

Please see full prescribing information, including BOXED WARNING, for LUVOX CR.

References:

  1. ^ Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003;64:640-647.
  2. ^ LUVOX CR Prescribing Information. Jazz Pharmaceuticals, Inc., Palo Alto, CA.
  3. ^ Davidson, J Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:118-125.
  4. ^ Westenberg HGM, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:49-55.

LUVOX CR is a registered trademark of Abbott Products, Inc.
CT STEPS is a registered trademark of Jazz Pharmaceuticals, Inc.
SODAS® is a registered trademark of Elan Pharma International Ltd. (EPIL). US Patent no 7,465,462.

The product information provided in this site is intended for residents of the United States only.
© 2008-2012 Jazz Pharmaceuticals, Inc. | Privacy Policy & Terms of Use | Sitemap | Contact us
Last update: June 09, 2011